Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Comparative Effectiveness In Coverage Decisions: Restrictions Added To House Health Reform Bill

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Federally-funded comparative effectiveness research could not be used by the government to "deny or ration care" or as the basis for making cost-driven coverage decisions, under amendments to the House health reform legislation adopted in markup.

You may also be interested in...



Comparative Effectiveness Research On Track To Be Resolved In Conference

Independent versus government-based CER group is one of issues likely to be left to House/Senate negotiators.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel

Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs

More Heartmate Troubles For Abbott. Latest Recall Includes 14 Deaths

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

See All
UsernamePublicRestriction

Register

PS069768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By